PRIMIDONE- primidone tablet PD-Rx Pharmaceuticals, Inc.

PRIMIDONE TABLETS, USP


50 mg and 250 mg

Anticonvulsant

Rx only

DESCRIPTION

Chemical name: 5-ethyldihydro-5-phenyl-4,6 (1H, 5H)-pyrimidinedione. Structural formula:



 $C_{12}H_{14}N_2O_2$

M.W. 218.25

Primidone is a white, crystalline, highly stable substance, M.P. 279-284°C. It is poorly soluble in water (60 mg per 100 mL at 37°C) and in most organic solvents. It possesses no acidic properties, in contrast to its barbiturate analog.

Primidone 50 mg and 250 mg tablets contain the following inactive ingredients: hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate and talc.

Primidone 250 mg tablets also contain D&C yellow #10 aluminum lake and FD&C yellow #5 aluminum lake.

ACTIONS

Primidone raises electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. The mechanism(s) of primidone's antiepileptic action is not known.

Primidone *per se* has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, PEMA potentiates the anticonvulsant activity of phenobarbital in experimental animals.

INDICATIONS AND USAGE

Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.

CONTRAINDICATIONS

Primidone is contraindicated in: 1) patients with porphyria and 2) patients who are hypersensitive to phenobarbital (see **ACTIONS**).

WARNINGS

The abrupt withdrawal of antiepileptic medication may precipitate status epilepticus. The therapeutic efficacy of a dosage regimen takes several weeks before it can be assessed.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including primidone, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 1 shows absolute and relative risk by indication for all evaluated AEDs.

Table 1 Risk by indication for antiepileptic drugs in the

	•	-		
Indication	Placebo Patients with Events Per 1000 Patients	Events Per 1000	Incidence of Events in Drug Patients/	Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9

pooled analysis

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing primidone or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Pregnancy

To provide information regarding the effects of *in utero* exposure to primidone, physicians are advised to recommend that pregnant patients taking primidone enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website <u>http://www.aedpregnancyregistry.org/</u>.

The effects of primidone in human pregnancy and nursing infants are unknown.

Recent reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.

The reports suggesting an elevated incidence of birth defects in children of drug-treated epileptic women cannot be regarded as adequate to prove a definite cause and effect relationship.

There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors leading to birth defects, e.g., genetic factors or the epileptic condition itself, may be more important than drug therapy. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorders are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus.

The prescribing physician will wish to weigh these considerations in treating or counseling epileptic women of childbearing potential. Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. Pregnant women under anticonvulsant therapy should receive prophylactic vitamin K1 therapy for one month prior to, and during, delivery.

PRECAUTIONS

The total daily dosage should not exceed 2 g. Since primidone therapy generally extends over prolonged periods, a complete blood count and a sequential multiple analysis-12 (SMA-12) test should be made every six months.

Primidone Tablets 250 mg contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Nursing Mothers

There is evidence in mothers treated with primidone, the drug appears in the milk in substantial quantities. Since tests for the presence of primidone in biological fluids are too complex to be carried out in the average clinical laboratory, it is suggested that the presence of undue somnolence and drowsiness in nursing newborns of primidone-treated mothers be taken as an indication that nursing should be discontinued.

Information for Patients

Suicidal Thinking and Behavior - Patients, their caregivers, and families should be counseled that AEDs, including primidone, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening

of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self- harm. Behaviors of concern should be reported immediately to healthcare providers.

Pregnancy - Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see **WARNINGS, Pregnancy** section).

Please refer to the Primidone Tablets, USP Medication Guide provided with the product for more information.

ADVERSE REACTIONS

The most frequently occurring early side effects are ataxia and vertigo. These tend to disappear with continued therapy, or with reduction of initial dosage. Occasionally, the following have been reported: nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, sexual impotency, diplopia, nystagmus, drowsiness and morbilliform skin eruptions. Granulocytopenia, agranulocytosis, and red-cell hypoplasia and aplasia, have been reported rarely. These and, occasionally, other persistent or severe side effects may necessitate withdrawal of the drug. Megaloblastic anemia may occur as a rare idiosyncrasy to primidone and to other anticonvulsants. The anemia responds to folic acid without necessity of discontinuing medication.

To report SUSPECTED ADVERSE REACTIONS, contact Oxford Pharmaceuticals, LLC at 1-844-508-1455, 8:00 AM to 4.30 PM ET, Monday - Friday or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

Usual Dosage

Patients 8 years of age and older who have received no previous treatment may be started on primidone according to the following regimen using either 50 mg or scored 250 mg primidone tablets:

Days 1 to 3: 100 to 125 mg at bedtime Days 4 to 6: 100 to 125 mg twice a day Days 7 to 9: 100 to 125 mg three times a day Day 10 to maintenance: 250 mg three times a day

For most adults and children 8 years of age and over, the usual maintenance dosage is three to four 250 mg primidone tablets in divided doses (250 mg t.i.d. or q.i.d.). If required, an increase to five or six 250 mg tablets daily may be made but daily doses should not exceed 500 mg q.i.d.

Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations of primidone may be necessary for optimal dosage adjustment. The clinically effective serum level for primidone is between 5 to 12 µg/mL.

INITIAL: ADULTS AND CHILDREN OVER

KEY: •=50 mg tablet; ●=250 mg tablet							
Day		1	2	3	4	5	6
AM					••	••	••
NOON							
PM		••	••	••	••	••	••
DAY		7	8	9	10	11	12
AM		••	••	••	\bullet	Adju	st to
NOON		••	••	••	lacksquare	-	enance
PM		••	••	••	ullet		

Patients Already Receiving Other Anticonvulsants

Primidone should be started at 100 to 125 mg at bedtime and gradually increased to maintenance level as the other drug is gradually decreased. This regimen should be continued until satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with primidone alone is the objective, the transition from concomitant therapy should not be completed in less than two weeks.

Pediatric Dosage

For children under 8 years of age, the following regimen may be used:

Days 1 to 3: 50 mg at bedtime.

Days 4 to 6: 50 mg twice a day

Days 7 to 9: 100 mg twice a day

Day 10 to maintenance: 125 mg three times a day to 250 mg three times a day

For children under 8 years of age, the usual maintenance dosage is 125 to 250 mg three times daily or, 10 to 25 mg/kg/day in divided doses.

HOW SUPPLIED

Primidone 50 mg Tablets, USP are white, round, flat faced, beveled edge, scored tablets debossed "684" above bisect on one side and "O" on the other side. Supplied in:

Bottles of 100, NDC 72789-178-01

Bottles of 500, NDC 72789-178-82

Primidone 250 mg Tablets, USP are yellow, round, flat faced, beveled edge, scored tablets debossed "685" above bisect on one side and "O" on the other side. Supplied in:

Bottles of 100, NDC 72789-177-01 Bottles of 500, NDC 72789-177-82

Storage

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container with a child-resistant closure.

Dispense with Medication Guide available at:https://www.oxford-rx.com/med-guides

MEDICATION GUIDE

Primidone Tablets, USP, 50 mg and 250 mg

Dispense with Medication Guide available at: https://www.oxford-rx.com/med-guides

Read this Medication Guide before you start taking primidone tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about primidone tablets?.

Like other antiepileptic drugs, primidone tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

- thoughts about suicide or dying
- attempts to commit suicide
- new or worse depression
- new or worse anxiety
- feeling agitated or restless
- panic attacks
- trouble sleeping (insomnia)
- new or worse irritability
- acting aggressive, being angry, or violent
- acting on dangerous impulses
- an extreme increase in activity and talking (mania)
- other unusual changes in behavior or mood

Do not stop primidone tablets without first talking to a healthcare provider.

• Stopping primidone tablets suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

How can I watch for early symptoms of suicidal thoughts and actions?

- Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
- Keep all follow-up visits with your healthcare provider as scheduled.
- Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

What are primidone tablets?

Primidone tablets are a prescription medicine used alone or with other medicines to treat people with:

- generalized tonic-clonic (grand mal) seizures
- complex partial (psychomotor) seizures
- partial (focal) epileptic seizures.

Who should not take primidone tablets?

Do not take primidone tablets if you:

- have a genetic disorder called porphyria
- are allergic to phenobarbital

What should I tell my healthcare provider before taking primidone tablets?

Before you take primidone tablets, tell your healthcare provider if you:

- have or have had depression, mood problems or suicidal thoughts or behavior
- have any other medical conditions
- are pregnant or planning to become pregnant. Primidone tablets may harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking primidone tablets. You and your healthcare provider will decide if you should take primidone tablets while you are pregnant.
 - If you become pregnant while taking primidone tablets, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.
- are breastfeeding or plan to breastfeed. Primidone can pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take primidone tablets.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking primidone tablets with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.

Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine.

How should I take primidone tablets?

Take primidone tablets exactly as prescribed. Your healthcare provider will tell you how much primidone tablets to take and when to take it.

- Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.
- Do not stop taking primidone tablets without first talking to your healthcare provider. Stopping primidone tablets suddenly can cause serious problems.
- If you take too much primidone tablets, call your healthcare provider or local Poison Control Center right away.

What should I avoid while taking primidone tablets?

- Primidone tablets can make you sleepy or dizzy. Do not drink alcohol or take other drugs that make you sleepy or dizzy while taking primidone tablets without first discussing this with your healthcare provider. Taking primidone tablets with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse.
- Do not drive, operate heavy machinery, or do other dangerous activities until you know how primidone tablets affect you. Primidone tablets can slow your thinking and motor skills.

What are the possible side effects of primidone tablets?

See "What is the most important information I should know about primidone tablets?".

Primidone tablets may cause other serious side effects including:

- Sleepiness that can be severe, especially when you first start taking primidone tablets.
- Primidone tablets may rarely cause blood problems. Symptoms may include:
 - fever, swollen glands, or sore throat that come and go or do not go away
 - frequent infections or an infection that does not go away
 - tiredness
 - shortness of breath
- Primidone tablets may rarely cause allergic reactions. Symptoms may include:
 - skin rash
 - hives
 - sores in your mouth
 - blistering or peeling skin

The most common side effects of primidone tablets include:

- problems with walking and moving
- feelings of dizziness, spinning, or swaying (vertigo)

These are not all the possible side effects of primidone tablets. For more information, ask your healthcare provider or pharmacist.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1- 800-FDA-1088.

How should I store primidone tablets?

Store primidone tablets at room temperature between 68°F to 77°F (20°C to 25°C) in a tight, light- resistant container.

Keep primidone tablets and all medicines out of the reach of children.

General Information about primidone tablets

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use primidone tablets for a condition for which it was not prescribed. Do not give primidone tablets to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about primidone

tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about primidone tablets that is written for health professionals.

For more information, call 1-844-508-1455, 8:00 AM to 4.30 PM ET, Monday – Friday.

What are the ingredients in Primidone?

Active Ingredient: primidone

Inactive ingredients: hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate and talc.

Primidone 250 mg tablets also contain D&C yellow #10 aluminum lake and FD&C yellow #5 aluminum lake.

Primidone Tablets 250 mg contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by: **OXFORD PHARMACEUTICALS, LLC** Birmingham, AL 35211

8200023 Rev 01

01/22

PRINCIPAL DISPLAY PANEL

Primidone Tablets, USP 50 mg ANTICONVULSANT PHARMACIST: DISPENSE THE ACCOMPANYING MEDICATION GUIDE TO EACH PATIENT Rx only Each Tablet Contains: Primidone, USP 50mg **USUAL DOSAGE:** See package insert.

Dispense in a well closed container with a child-resistant closure.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

3

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. 72789 17882



Rx Only

0

500 Tablets



Pharmacist: Dispense The Medication Guide Provided Separately To Each Patient



GTIN: 00372789178820 SNO: 124B85000303 EXP: 12/2025 LOT: 124B85

Please direct all product inquiries

to PD-Rx Pharmaceuticals, Inc. Marketed and Packaged By:

PD-Rx Pharmaceuticals. Inc

Oklahoma City, OK 73127

Manufactured by:

1-405-942-3040 V.8.19.4

Oxford Pharmaceuticals, LLC

Birmingham, Alabama 35211

Print Patient Information Guide at:

https://www.oxford-rx.com/med-guides

Primidone Tablets, USP 250 mg

Each Tablet Contains: Primidone, USP 250mg Contains FD&C Yellow No. 5 (Tartrazine) as a color additive

USUAL DOSAGE: See package insert.

Dispense in a well closed container with a child-resistant closure.

Store at 20° to 25°C (68° to 77°F) [See **USP** Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.





PRIMIDONE

primidone tablet

	ormation							
Product Type				NDC:7278 684)	NDC:72789-178(NDC:69584- 684)			
Route of Adm	inistration	ORAL						
Active Ingre	dient/Activ	e Moiety						
		Basis	of Strer	ngth	Strengt			
PRIMIDONE (UNII: 13AFD7670Q) (PRIMIDONE - UNII:13AFD7670Q) PRIMIDONE							50 mg	
Inactive Ing	redients							
		Ingredient Na	mo				Strength	
Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)							Strength	
								
	-	SE 101 (UNII: 7T9FYH5Q	MK)					
MAGNESIUM ST								
SODIUM LAURYL SULFATE (UNII: 368GB5141J)								
SODIUM STARC	H GLYCOLATE	TYPE A POTATO (UNII: !	5856J3G2A2)					
TALC (UNII: 7SE)	/7J4R1U)							
Product Cha	racteristic	S						
		S vhite Scor	e		2	pieces		
Color	v	-	e			pieces mm		
Color Shape	v	vhite Scor COUND Size	e int Code		71	-		
Color Shape Flavor	v	vhite Scor COUND Size	-		71	mm		
Color Shape Flavor	v	vhite Scor COUND Size	-		71	mm		
Color Shape Flavor Contains	v	vhite Scor COUND Size	-		71	mm		
Color Shape Flavor Contains Packaging	v R	vhite Scor COUND Size	int Code	Marketing	71 63 Start	mm 84;O	ceting End Date	
Color Shape Flavor Contains Packaging # Item Code	v R	Vhite Scor COUND Size Impr Package Descriptio TLE, PLASTIC; Type 0: No	int Code n	-	71 63 Start	mm 84;O	-	
Color Shape Flavor Contains Packaging # Item Code 1 NDC:72789- 178-01	P 100 in 1 BOT Combination	Package Descriptio	int Code n t a	Date	71 63 Start	mm 84;O	-	
Color Shape Flavor Contains Packaging # Item Code 1 NDC:72789- 178-01 2 NDC:72789-	P R 100 in 1 BOT Combination 500 in 1 BOT	Package Descriptio	int Code n t a	Date 03/30/2021	71 63 Start	mm 84;O	-	
Color Shape Flavor Contains Packaging # Item Code 1 NDC:72789- 178-01 2 NDC:72789- 178-82	100 in 1 BOT Combination 500 in 1 BOT Combination	ACUND Size ACUND Size Impr Package Descriptio TLE, PLASTIC; Type 0: No Product TLE, PLASTIC; Type 0: No Product	int Code n t a	Date 03/30/2021	71 63 Start	mm 84;O	-	
 NDC:72789- 178-01 NDC:72789- 	100 in 1 BOT Combination 500 in 1 BOT Combination 500 in 1 BOT Combination	ACUND Size ACUND Size Impr Package Descriptio TLE, PLASTIC; Type 0: No Product TLE, PLASTIC; Type 0: No Product	int Code n t a t a	Date 03/30/2021	5tart	mm 84;0 Mark	ceting End Date ceting End Date	

PRIMIDONE

primidone tablet

Product Information

Product Type		HUMAN PRES DRUG			NDC:727 685)	IDC:72789-177(NDC:69584- 85)				
Route of Admir	nistration	ORAL								
Active Ingred	lient/Activ	e Moiety								
Ingredient Name					Basis of Strength		ngth	Strength		
PRIMIDONE (UNII: 13AFD7670Q) (PRIMIDONE - UNII:13AFD7670Q)					PRIMIDON	ΙE		250 mg		
Inactive Ingr	edients									
Ingredient Name								Strength		
LACTOSE MONOI	HYDRATE (UN	III: EWQ57Q8I5X)								
HYPROMELLOSE	-		· · · · · · · · · · · · · · · · · · ·							
MICROCRYSTALL			T9FYH5QMK)							
MAGNESIUM STE										
SODIUM LAURYL										
SODIUM STARCH		Ι ΥΡΕ Α ΡΟΤΑΤ	U (UNII: 5856).	3G2A2)						
TALC (UNII: 7SEV7	-									
D&C YELLOW NO	D. TO ALOMIN	UM LAKE (UNII:								
FD&C YELLOW N	O. 5 (UNII: 175									
		53WB2F1M)								
Product Char	acteristic	53WB2F1M)	Score			2	2 pieces			
Product Char Color	acteristic y	53WB2F1M) S					2 pieces 10mm			
Product Char Color Shape	acteristic y	53WB2F1M) S rellow	Score]				
Product Char Color Shape Flavor	acteristic y	53WB2F1M) S rellow	Score Size]	10mm			
Product Char Color Shape Flavor	acteristic y	53WB2F1M) S rellow	Score Size]	10mm			
Product Char Color Shape Flavor Contains	acteristic y	53WB2F1M) S rellow	Score Size]	10mm			
Product Char Color Shape Flavor Contains Packaging	r acteristic y R	53WB2F1M) S rellow	Score Size Imprint C	ode	1arketing Date	1 (Start	10mm 585;O			
Product Char Color Shape Flavor Contains Packaging	racteristic y R	53WB2F1M) S rellow ROUND Package Des TLE, PLASTIC; Ty	Score Size Imprint C	ode	-	1 (Start	10mm 585;O	keting End		
Product Char Color Shape Flavor Contains Packaging # Item Code 1 NDC:72789- 177-01	Tacteristic y R 100 in 1 BOT Combination	53WB2F1M) S rellow ROUND ROUND TLE, PLASTIC; Ty Product TLE, PLASTIC; Ty	Score Size Imprint C	2 ode M 03/	Date	1 (Start	10mm 585;O	keting End		
Product Char Color Shape Flavor Contains Packaging # Item Code 1 NDC:72789- 177-01 2 NDC:72789-	Tacteristic y R 100 in 1 BOT Combination 500 in 1 BOT	53WB2F1M) S rellow ROUND ROUND TLE, PLASTIC; Ty Product TLE, PLASTIC; Ty	Score Size Imprint C	2 ode M 03/	Date /30/2021	1 (Start	10mm 585;O	keting End		
Product Char Color Shape Flavor Contains Packaging # Item Code 1 NDC:72789- 177-01 2 NDC:72789- 177-82	acteristic y R 100 in 1 BOT Combination 500 in 1 BOT Combination	S rellow ROUND Package Des TLE, PLASTIC; Ty Product TLE, PLASTIC; Ty Product	Score Size Imprint C	2 ode M 03/	Date /30/2021	1 (Start	10mm 585;O	keting End		
1 NDC:72789- 177-01 2 NDC:72789-	acteristic y R 100 in 1 BOT Combination 500 in 1 BOT Combination	S rellow ROUND Package Des TLE, PLASTIC; Ty Product TLE, PLASTIC; Ty Product	Score Size Imprint C Socription ype 0: Not a ype 0: Not a	Code 03, 06,	Date /30/2021	Start	10mm 585;0 Marl	keting End		

Labeler - PD-Rx Pharmaceuticals, Inc. (156893695)

Registrant - PD-Rx Pharmaceuticals, Inc. (156893695)

Establishment							
Name	Address	ID/FEI	Business Operations				
PD-Rx Pharmaceuticals, Inc.		156893695	repack(72789-177, 72789-178)				

Revised: 9/2024

PD-Rx Pharmaceuticals, Inc.